Back

Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: What’s new on lipids and diabetes in acute coronary syndrome Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

5 More presentations in this session

Presentation thumbnail
Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and interaction with the vascular endothelium: the impact of PCSK9 inhibition with evolocumab in acute coronary syndrome
Doctor E. Ziogos (Baltimore, US)
Abstract Slides Video
Presentation thumbnail
Quality matters: low-density lipoprotein electronegativity but not quantity determines mortality risk in acute coronary syndromes
Doctor S. Kraler (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Glycated haemoglobin and the association with long-term survival among patients evaluated for stable angina - a prospective Norwegian cohort
Doctor G. Svingen (Bergen, NO)
Abstract Slides Video
Presentation thumbnail
Cardioprotective effect of empagliflozin in acute myocardial infarction: the role of ketone bodies availability.
Professor J. Badimon (New York City, US)
Abstract Slides Video
Presentation thumbnail
Impact of chronic GLP-1 receptor agonist and SGLT-2 inhibitor therapy on in-hospital outcomes of patients with diabetes mellitus hospitalized with acute myocardial infarction.
Doctor F. Trombara (Milan, IT)
Abstract Slides Video

Access the full session

Session thumbnail
What’s new on lipids and diabetes in acute coronary syndrome

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Elevated lipoprotein(a) identifies patients with acute coronary syndrome who derive earlier and greater cardiovascular benefit of alirocumab, particularly for limb events
thumbnail
Congress Presentation
Case 1 - recurrent acute coronary syndrome in a patient with familial hypercholesterolaemia and high lipoprotein(a): the Turkish perspective
thumbnail
Congress Presentation
Two of a kind: mass and molar immunoassay-based lipoprotein (a) concentrations are similarly prognostic for MACE risk and predictive of alirocumab benefit in ODYSSEY OUTCOMES

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources